Business Description
Sonnet BioTherapeutics Holdings Inc
NAICS : 541714
SIC : 8731
ISIN : US83548R3030
Share Class Description:
FRA:H3D: Ordinary SharesDescription
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.14 | |||||
| Equity-to-Asset | -0.18 | |||||
| Debt-to-Equity | -0.27 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -67.9 | |||||
| Beneish M-Score | -3.35 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -91.6 | |||||
| 3-Year EBITDA Growth Rate | 80.7 | |||||
| 3-Year EPS without NRI Growth Rate | 83.4 | |||||
| 3-Year FCF Growth Rate | 82 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -6.11 | |||||
| 12-1 Month Momentum % | -71.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.66 | |||||
| Quick Ratio | 0.66 | |||||
| Cash Ratio | 0.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -198.5 | |||||
| Shareholder Yield % | -79.62 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -62368.42 | |||||
| Net Margin % | -39152.63 | |||||
| FCF Margin % | -46335.29 | |||||
| ROE % | -493.83 | |||||
| ROA % | -147.34 | |||||
| ROIC % | -906.38 | |||||
| ROC (Joel Greenblatt) % | -6364.12 | |||||
| ROCE % | -742.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 40 | |||||
| EV-to-EBIT | -0.37 | |||||
| EV-to-EBITDA | -0.37 | |||||
| EV-to-Revenue | 230.11 | |||||
| EV-to-FCF | -0.51 | |||||
| Earnings Yield (Greenblatt) % | -270.27 | |||||
| FCF Yield % | -178.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sonnet BioTherapeutics Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.017 | ||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 148.59 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 5.412 | ||
| 12-1 Month Momentum % | -71.4 | ||
| 52-Week Range (€) | 3.475999 - 21.669999 | ||
| Shares Outstanding (Mil) | 3.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sonnet BioTherapeutics Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sonnet BioTherapeutics Holdings Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sonnet BioTherapeutics Holdings Inc Frequently Asked Questions
What is Sonnet BioTherapeutics Holdings Inc(FRA:H3D)'s stock price today?
The current price of FRA:H3D is €5.41. The 52 week high of FRA:H3D is €21.67 and 52 week low is €3.48.
When is next earnings date of Sonnet BioTherapeutics Holdings Inc(FRA:H3D)?
The next earnings date of Sonnet BioTherapeutics Holdings Inc(FRA:H3D) is 2025-02-14 Est..
Does Sonnet BioTherapeutics Holdings Inc(FRA:H3D) pay dividends? If so, how much?
Sonnet BioTherapeutics Holdings Inc(FRA:H3D) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers